• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CRYOLIFE, INC. HERO GRAFT; VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CRYOLIFE, INC. HERO GRAFT; VASCULAR GRAFT Back to Search Results
Model Number HERO 1001
Device Problem Device Operates Differently Than Expected (2913)
Patient Problems Abscess (1690); Unspecified Infection (1930); Occlusion (1984); Seroma (2069); Thrombosis (2100); Stenosis (2263); Impaired Healing (2378); Pseudoaneurysm (2605)
Event Date 09/17/2010
Event Type  Injury  
Event Description
According to the publication, experience of hero dialysis graft placement in a challenging population, a total of 11 patients underwent 12 hero graft implants.All of the patients had cvod to varying extents, including subclavian vein stenosis or occlusion, innominate vein stenosis and superior vena cava stenosis.All of these patients had multiple vascular accesses (catheters and av fistulasd or grafts) placed prior to the hero, with a minimum of 2 and a maximum of >14.Only 3 patients had a history of bacteremia, leading to removal of their access prior to hero placement.Reasons for reintervention or failure (n=11): thrombosis (total of 5 events, number of failed grafts 4), local infection (total of 3 events, number of failed grafts 3), pseudoaneurysm (total of 2 events), seroma (total of 1 event), hematoma (total of 1 event) and nonhealing incision (total of 1 event).Associated with the local infection the paper added the following information "grafts removed due to abcess formation over graft." this medwatch is being submitted for the seroma event.
 
Manufacturer Narrative
This investigation is currently ongoing.Any additional information will be provided in the follow-up report.
 
Manufacturer Narrative
According to the publication, "experience of hero dialysis graft placement in a challenging population," a total of 11 patients underwent 12 hero graft implants.All of the patients had cardiovascular occlusive disease (cvod) to varying extents, including subclavian vein stenosis or occlusion, innominate vein stenosis and superior vena cava stenosis.All of these patients had multiple vascular accesses (catheters and arteriovenous [av] fistulas or grafts) placed prior to the hero, with a minimum of 2 and a maximum of >14.Only 3 patients had a history of bacteremia, leading to removal of their access prior to hero placement.Reasons for re-intervention or failure (n=11): thrombosis (total of 5 events, number of failed grafts 4), local infection (total of 3 events, number of failed grafts 3), pseudoaneurysm (total of 2 events), bacteremia (total of 2 events), seroma (total of 1 event), hematoma (total of 1 event) and nonhealing incision (total of 1 event).Associated with the local infection the paper added the following information "grafts removed due to abscess formation over graft." this medwatch represents 1 seroma event.Both hero 1001 and hero 1002 were investigated as it could not be determined which component, if either contributed to the reported event.Additional information was provided from the surgeon and it was determined that this event represents patient 2 in the study.Patient 2 was a male who had a hero graft (hero 1001, lot 001184 and hero 1002, lot 0001186) implanted on (b)(6) 2010.The patient has had multiple complications including thrombosis, pseudoaneurysm, bacteremia, seroma, and hematoma.Bacteremia was identified on (b)(6) 2011 and the hero graft was cannulated during bacteremia.Blood culture results gram positive cocci however, urine culture results no growth.A second bacteremia incident occurred (b)(6) 2011 and the hero graft was not cannulated during.Blood culture results gram positive cocci.A third bacteremia incident occurred (b)(6) 2011 and the hero graft was cannulated during.Blood culture results gram positive cocci.Two seromas were identified in the patient on (b)(6) 2010 and (b)(6) 2011; both seromas were located near right upper extremity near location of arterial anastomosis.Three hematomas were identified on (b)(6) 2010, (b)(6) 2014 and (b)(6) 2015.The hematomas occurred in the right upper extremity around arterial end of graft, in the right upper extremity near arterial anastomosis but did not involve graft, and in the right upper extremity around distal third of graft segment.A mechanical thrombectomy and revision of the graft occurred on (b)(6) 2014 for thrombosis.Pseudoaneurysms were identified on (b)(6) 2014, (b)(6) 2015, during all three of which the hero was cannulated during.Each event which occurred in patient 5 is submitted in a separate medwatch.This medwatch represents the seroma identified on (b)(6) 2010.The manufacturing records for lots hero 1001, lot 001184 and hero 1002, lot 0001186 were reviewed, and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.The ifu also lists pseudoaneurysm and seromas as potential vascular graft and catheter complications.Four seroma cases were reported in 2 patients.Two patients had multiple seromas.Seroma is a known early complication of expanded polytetrafluoroethylene grafts.Patient medical history is unknown.At this time, the role of the hero graft in these complications cannot be determined due to the aforementioned unknowns.The root cause for the reported event is unknown; however, all complications noted in the complaint are known potential complication of the hero graft.The ifu lists the following potential complications with the use of the hero graft: seroma, infection, vascular graft revision/replacement, partial stenosis or full occlusion of prosthesis or vasculature, pseudoaneurysm, hematoma, and abnormal healing.The hero graft is unlikely to be the direct source of the infection as the product undergoes a validated terminal sterilization process.There is no indication that an error or deficiency occurred at cryolife and the ifu adequately communicates risk.
 
Event Description
According to the publication, experience of hero dialysis graft placement in a challenging population, a total of 11 patients underwent 12 hero graft implants.All of the patients had cvod to varying extents, including subclavian vein stenosis or occlusion, innominate vein stenosis and superior vena cava stenosis.All of these patients had multiple vascular accesses (catheters and av fistulas or grafts) placed prior to the hero, with a minimum of 2 and a maximum of >14.Only 3 patients had a history of bacteremia, leading to removal of their access prior to hero placement.Reasons for reintervention or failure (n=11): thrombosis (total of 5 events, number of failed grafts 4), local infection (total of 3 events, number of failed grafts 3), pseudoaneurysm (total of 2 events), seroma (total of 1 event), hematoma (total of 1 event) and nonhealing incision (total of 1 event).Associated with the local infection the paper added the following information "grafts removed due to abcess formation over graft." this medwatch is being submitted for the seroma event.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
HERO GRAFT
Type of Device
VASCULAR GRAFT
Manufacturer (Section D)
CRYOLIFE, INC.
1655 roberts blvd., nw
kennesaw GA 30144
Manufacturer (Section G)
CRYOLIFE, INC.
1655 roberts blvd., nw
kennesaw GA 30144
Manufacturer Contact
sandra o'reilly
1655 roberts blvd., nw
kennesaw, GA 30144
MDR Report Key4826339
MDR Text Key5838694
Report Number1063481-2015-00084
Device Sequence Number1
Product Code DSY
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K124039
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Health Professional
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 06/01/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Physician
Device Model NumberHERO 1001
Device Lot Number0001184
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 06/01/2015
Initial Date FDA Received06/09/2015
Supplement Dates Manufacturer ReceivedNot provided
Supplement Dates FDA Received07/31/2015
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
-
-